We use first- and third-party cookies to provide our services and collect statistical data. By continuing to browse you accept these cookies. More information Accept
Expertise /DEVELOPMENT & MANUFACTURING /Respiratory APIs

RESPIRATORY APIs FOR INHALATION

The NuPharm Group, through its API subsidiary Inke, has specialised in the development and
manufacture of active substances for use in respiratory inhalation therapies for the last two decades

INKE IS A KEY SUPPLIER TO MAJOR GENERIC AND BRANDED COMPANIES WORLDWIDE.

IN-HOUSE MICRONISATION EXPERTISE

Over 20 years' experience in in-house micronisation technology at Inke means we can provide:
  • Isolation, final treatment and analysis of active substances for use in respiratory therapies performed in special containment facilities

  • Process control of micronisation grades achieved to ensure that each active substance conforms to custom particle size distribution specification

  • Control amorphous content and other relevant parameters for particle size stability for suitable formulation purposes
  • Certifications: EU-GMP, last FDA inspection April 2016, ISO 9001, ISO 14001, Certificates of Suitability (CEPs).
    Policies: Quality, HSE
  • Customised products and technical support

  • RESPIRATORY_METAS_MICRONISATION_ALT_LIST06 Various patent applications

HIGH-ADDED VALUE ACTIVE SUBSTANCES FOR USE IN RESPIRATORY THERAPIES

Given the stringent requirements for inhalators, our strategic commitment ensures a high level of our technical and regulatory standards making Inke a leading manufacturer in respiratory APIs
LEARN MORE ABOUT INKE